Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 9,935 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: Advance Care Planning
Interventions: Trauma-Informed Care-adapted and Checklist-guided ACP intervention; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions: TC-510, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: TCR2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more

Conditions: IgG4 Related Disease
Interventions: ACE1831, Lymphodepleting chemotherapy; Drug
Lead sponsor: Acepodia Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases, Chronic Myelomonocytic Leukemia
Interventions: Decitabine, PDR001, MBG453, Azacitidine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • Portland, Oregon • Houston, Texas

Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
Interventions: Azacitidine (AZC), Decitabine, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 4
States / cities: Scottsdale, Arizona • Cleveland, Ohio • Seattle, Washington

Conditions: Total Knee Replacement
Interventions: Bone wax; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Syosset, New York

Conditions: Family Characteristics, Health Status, Family Research
Interventions: Electronic Health Portals for collecting Family History data; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Lifestyle, Sedentary Behavior
Interventions: CBPA + family support, CBPA; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Type II Diabetes, Periodontal Disease
Interventions: Motivational Interviewing, Dental cleaning; Behavioral · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Physical Inactivity
Interventions: Comparator Arm, Enhanced intervention arm; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: New York, New York

Conditions: Acute Kidney Injury Due to Sepsis
Interventions: TIN816 70 mg lyophilisate powder, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more

Conditions: High Blood Pressure
Interventions: Coffee; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion, Acute Rejection of Lung Transplant (Disorder), Airway Obstruction, Rib Fractures, Acute Copd Exacerbation, Asthma COPD, Pulmonary Embolism, Hemothorax, Pneumothorax, Mesothelioma, Diaphragmatic Paralysis
Interventions: Portable Dynamic Digital Radiography (DDR); Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions: ERX-963, Placebo; Drug
Lead sponsor: Expansion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more

Conditions: Melanoma
Interventions: TNFerade™; Drug
Lead sponsor: GenVec; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Anemia
Interventions: Brand sodium ferric gluconate, Generic sodium ferric gluconate; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: BIBW 2992; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 23
States / cities: Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more

Conditions: Stress, Burnout, Professional
Interventions: yogic breathing; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Major Depression
Interventions: Virtual reality; Behavioral
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine; Other
Eligibility: 13 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Washington, Iowa

Conditions: Bladder Cancer Requiring Cystectomy, Ureteral Stents
Interventions: ureteral stents, no ureteral stent; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 78
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more

Conditions: Primary Dysmenorrhea
Interventions: Pau d' Arco; Dietary Supplement
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Grief, Post Traumatic Stress Disorder, Suicidal Ideation, Miscarriage, Stillbirth, Infant Death
Interventions: Along With Me, Peer Guide; Behavioral
Lead sponsor: Oregon Research Behavioral Intervention Strategies, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Eugene, Oregon • Springfield, Oregon

Conditions: Eating Disorder
Interventions: Training, Training and Technical Assistance, Training, Tech. Assistance, Quality Assurance/Improvement; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 17 Years and older
Enrollment: 2,261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Stanford, California • Eugene, Oregon • Austin, Texas + 1 more

Search by objective public record fields.

The R4R Advance Care Planning Pilot Study

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty

Integrating Patient Generated Family Health History From Varied Electronic Health Record (EHR) Entry Portals

Stay Active Physical Activity Program

Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes

Free Time For Wellness 2+

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

Effects of High Caffeine Content Coffee on Blood Pressure in Young Adults

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

TNFerade™ Biologic Plus Radiation for Metastatic Melanoma

IV Iron Safety: Evaluation of Iron Species in Healthy Subjects

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Using Yogic Breathing to Reduce Stress in Anesthesia Personnel As Measured by Hair Cortisol

Evaluation of an 8-week Behavior Skills-based Virtual Reality Program for Adolescents With Depression. (MDD)

STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Effects of Pau d' Arco in Primary Dysmenorrhea

Walk With Me (WWM) for Perinatal Grief

Implementation Support for Prevention Program Delivery by College Peer Educators